Femoston Conti is a continuous combined hormone replacement therapy (HRT) containing estradiol (estrogen) and dydrogesterone (progestogen). It is indicated for use in postmenopausal women (at least 12 months since last natural period) to relieve menopausal symptoms such as hot flushes, night sweats, and vaginal dryness. It also helps prevent postmenopausal osteoporosis in women at increased risk of fractures.
Take one tablet daily, at approximately the same time each day.
Tablets are taken continuously without a break between packs.
Swallow whole with water; can be taken with or without food.
If a dose is missed and less than 12 hours have passed, take it as soon as remembered. If more than 12 hours, skip the missed dose and continue as normal.
Treatment should be reviewed regularly, using the lowest effective dose for the shortest duration consistent with treatment goals.
Femoston Conti should not be used in patients with:
Known, past, or suspected breast cancer
Known or suspected oestrogen-dependent tumours (e.g., endometrial cancer)
Undiagnosed vaginal bleeding
Untreated endometrial hyperplasia
Active or previous venous thromboembolism (DVT/PE)
Known thrombophilic disorders
Active or recent arterial thromboembolic disease (e.g., stroke, MI)
Acute liver disease or history of liver disease until liver function normalises
Known hypersensitivity to any component of the product
Common:
Headache Nausea Breast tenderness Abdominal pain Back pain
Uncommon/Serious:
Venous thromboembolism (DVT/PE) Stroke or myocardial infarction Gallbladder disease Increased risk of breast cancer (with long-term use) Irregular breakthrough bleeding or spotting (especially in early months)
Patients should be advised to seek urgent medical attention if they experience symptoms suggestive of thrombosis, stroke, or severe allergic reaction.
